7 news items
Galapagos presents encouraging new data for CD19 CAR-T candidate GLPG5101 in non-Hodgkin lymphoma at EHA 2024
GLPG
14 Jun 24
vein-to-vein time of seven days, eliminating the need for bridging therapy. T-cell subsets were assessed in the apheresis starting material and final
Galapagos and Adaptimmune sign clinical collaboration agreement with an option to exclusively license Adaptimmune's TCR T-cell therapy candidate, uza-cel, in head & neck cancer and potential future solid tumor indications
ADAP
GLPG
30 May 24
and unknown risks, uncertainties and other factors which might cause Galapagos' actual results to be materially different from those expressed
Adaptimmune and Galapagos Sign Clinical Collaboration Agreement with an Option to Exclusively License Adaptimmune's TCR T-cell Therapy Candidate, uza-cel, in Head & Neck Cancer and Potential Future Solid Tumor Indications
ADAP
GLPG
30 May 24
involve certain risks and uncertainties. Such risks and uncertainties could cause our actual results to differ materially from those indicated
Galapagos and Blood Centers of America announce strategic collaboration to accelerate Galapagos' decentralized CAR-T manufacturing network in the U.S.
GLPG
15 May 24
offerings related to starting material, testing, quality control, cryopreservation, manufacturing and clinical applications. To learn more, visit
Galapagos reports first quarter 2024 financial results
GLPG
2 May 24
cause our actual results, financial condition and liquidity, performance or achievements, or the industry in which we operate, to be materially different
5jbi50g1kcifjxelzzklfzbeuo
GLPG
4 Apr 24
' actual results to be materially different from those expressed or implied by such forward-looking statements. These risks, uncertainties and other
whsew4yq8t8 ieuk5ide3221cljk
GLPG
26 Mar 24
, performance, or achievements to be materially different from any historic or future results, performance, or achievements expressed or implied
- Prev
- 1
- Next